Pharma's R&D Heartburn Spells Opportunity for GI-Focused Biotechs

Some Big Pharma have looked at the risk-reward equation for gastrointestinal R&D and they have opted out. But GI still represents a massive opportunity for Big Pharma, both in terms of its traditional primary care strengths and more recent forays into specialist medicine. This combination should open up new doors for GI-focused biotech players, several of which feel they can succeed where pharma has failed in tricky areas like IBS, with next generation drugs. Others have hitched their stars to commercially unvalidated targets, exploring new and potentially lucrative mechanisms of action.

By Christopher Morrison

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo